Serenus Biotherapeutics Strengthens Leadership With Appointments to Board and Management

Serenus Biotherapeutics Strengthens Leadership With Appointments to Board and 
Management 
Company Adds Team Members With Extensive Knowledge of Sub-Saharan
African Markets and Global Biopharmaceutical Industry 
SAN FRANCISCO, CA and JOHANNESBURG, SOUTH AFRICA -- (Marketwired) --
07/24/14 --  Serenus Biotherapeutics, Inc., a specialty
biopharmaceutical company bridging the divide between the world's
leading pharmaceutical markets and the growing demand for access to
innovative therapies in the emerging nations of Sub-Saharan Africa,
today announced appointments to its board of directors and senior
management team.  
The company named to its board of directors Sbu Luthuli, former
Chairman of Cipla Medpro; Dr. Nigel Fleming, founder and former
Chairman of Athena Diagnostics; and Kazuhiro Umeda, former President
of JAIC Singapore, Indonesia, and Thailand. 
In addition, the company made appointments to its executive
management team. It named Moosa Areff, who most recently served as
CEO of Ranbaxy South Africa's Sonke Pharmaceuticals subsidiary, as
its Chief Operating Officer. It also named Andrew de Pao, who served
as Head of Marketing of the Prescription Division at Cipla South
Africa, as its Chief Business Officer; and Nahum Johnson, former
Business Unit Manager - State Institutional and Government at Cipla
Medpro, as Director State and Institutional Business. 
"We are pleased to have attracted a distinguished group of board
members to guide us as we begin to implement our plans, enter into
new partnerships, and grow our company," says Dr. Menghis Bairu,
founder, Chairman, and CEO of Serenus Biotherapeutics. "The additions
we have made to our executive team give us the people on the ground
with intimate knowledge of the Sub-Saharan African landscape needed
to execute on our strategy." 
Mr. Luthuli noted that the appointments come as the Sub-Saharan
African market is experiencing rapid economic development, the
emergence of a burgeoning middle class, and a marked shift in disease
profiles.  
"The Sub-Saharan African pharmaceutical market is growing rapidly as
lifestyle changes are driving a shift in disease burden from
infectious to chronic diseases. Nevertheless, access to needed
innovative therapeutics is still limited today," says Mr. Luthuli.
"Serenus offers an African access platform that uniquely positions it
to serve as a partner of choice for biopharmaceutical companies with
innovative therapies in developed markets that appreciate the
opportunities in the emerging markets of Sub-Saharan Africa, but may
not have the expertise or networks needed to address the complexity
of doing business in the region."  
Below are bios of the Serenus Biotherapeutics appointees announced
today.  
Sbu Luthuli 
 Member of the Board of Directors
 Mr. Luthuli is the
CEO and Principal Officer of the Eskom Pension and Provident Fund,
one of the largest self-administered pension funds in South Africa
with assets under management in excess of $10.4 billion (R110
billion). Prior to this, he served as CEO of Ithala Bank Limited,
where he transformed and grew the bank through the launch of new
products and the introduction of electronic banking. He is a director
at Telkom SA Limited and also serves as the Vice Chairman of Batseta,
an industry organization representing pension fund trustees and
principal officers. He was involved with Cipla Medpro (formerly
Enaleni Pharmaceuticals Limited) for ten years and served as Chairman
of the Board of Directors until its sale to Cipla India in 2013. 
Dr. Nigel Fleming 
 Member of the Board of Directors
 Dr. Fleming is
founder and Chairman of G2B Pharma Inc., which is reformulating
off-patent drugs to significantly improve their safety or efficacy.
He founded and served as Chairman of Athena Diagnostics, a leading
provider of advanced neurodiagnostic tests, used for neuromuscular
and metabolic diseases. Dr. Fleming has served on various boards,
including Exemplar, Impax Labs, Genmedica Therapeutics, A-Cube,
Minoryx Therapeutics (as Chairman), and the Institute for OneWorld
Health. He has also served as a Lecturer at Harvard Medical School.
He earned his Ph.D. in Clinical Biochemistry from Cambridge
University, and completed a post-doctoral fellowship at Boston
University Medical School. 
Kazuhiro Umeda 
 Member of the Board of Directors
 Mr. Kazuhiro in
2005 joined Japan Asia Investment Co. Ltd., one of Japan's largest
Venture Capital Firms. He served as Head of the CEO's Office, as well
as President, heading up the Japan Asia Investment Company's
Singapore, Indonesia, and Thailand office. He also founded Apricot, a
natural food and drink company as a vehicle for commonly used
pharmaceuticals, a revolutionary approach for pharmaceutical dosing.
His early career included sales promotion for Daiichi Pharmaceuticals
Group of Japan. He earned a master's and bachelor's degree in life
sciences from the Tokyo University of Pharmacy and Life Sciences. 
Moosa Areff 
 Chief Operating Officer
 Mr. Areff comes to Serenus
with 18 years of experience in the biopharmaceutical industry,
starting as a sales representative and ultimately rising to become
CEO at Ranbaxy South Africa's Sonke Pharmaceuticals. During his
career he led the team that marketed and sold the first South African
over-the-counter product in the Middle East and Africa and also
negotiated and sold the first voluntarily licensed antiretroviral
products into Sub-Saharan Africa. Mr. Areff served as Aspen
Pharmacare's sales and marketing country manager for Nigeria, Uganda,
and Libya for the launch of Gilead Sciences' Viread and Truvada. He
also served as senior executive of new business development for Cipla
Medpro and led commercial due diligence of the sale of Cipla Medpro
to Enaleni Pharma. He has a diploma in journalism from Damelin
College. 
Andrew de Pao
 Chief Business Officer
 Mr. de Pao served as Head of
Marketing for the Prescription Division at Cipla South Africa, as
well as the commercial lead for Cipla South Africa Biosimilars Task
Team. While there, he spearheaded the development and implementation
of peri-, pre-, and post-launch clinical, marketing and communication
campaigns across all prescription and OTX disease categories. Prior
to joining Cipla South Africa, Mr. de Pao held a Healthcare
Communications Consultant and Directors position at Publicis Global
Healthcare Communications Group in the United Kingdom, where his team
was involved in development of Global Brand Communication Strategies
for various multinational pharmaceutical companies and provided
corporate brand positioning and development and execution of digital
and social media programs. He holds a Bachelor's in Physiology and
Biochemistry and a Master's in Physiology from the University of
Stellenbosch, South Africa.  
Nahum Johnson
 Director State and Institutional Business
 Mr. Johnson
has 20 years of experience in the biopharmaceutical industry. He most
recently served as Pharma Unit Manager-State Institutional and
Government at Cipla Medpro. Prior to that, he served as Key Account
Manager-Public Sector for Adcock Ingram. He has a Bachelor's in
Biochemistry from the University of the Western Cape, a postgraduate
degree in Management Development Practice from the Department of
Management Sciences, Business Graduate School UNISA; and is currently
completing a Master's in Information Systems Knowledge Management.  
About Serenus Biotherapeutics
 Serenus Biotherapeutics is a privately
held specialty biopharmaceutical company that specializes in
late-stage drug development, in-licensing, registering, and
commercializing therapies approved in the United States, Europe, and
Japan to address unmet medical needs with high regional prevalence in
the Sub-Saharan African market. For more information, please visit
www.serenusbio.com  
Contact:
Daniel Levine
Levine Media Group
(510) 280-5405
danny@levinemediagroup.com  
 
 
Press spacebar to pause and continue. Press esc to stop.